Abortus Brucella vaccine strain S19 marked recombinant strain and application thereof

Abstract

The invention discloses an abortus Brucella vaccine strain S19 marked recombinant strain and an application thereof. The abortus Brucella recombinant strain is a strain obtained by deactivating the glucosyltransferase coding gene. The obtained recombinant strain has small virulence and can be used as vaccines to immunize animals without needs of deactivation. When the recombinant strain is used for immunizing rats, the inoculated animal generates no lipopolysaccharide antibody and the virulent virus strain-infected animal can be distinguished from novel vaccine strain immunized animal by serological reaction. The recombinant strain is beneficial to improving the Brucella vaccine, researching diagnosis and identification reagents and developing the Brucella vaccine and matched diagnosis and identification reagents, and has extremely important significance in deracinating and purifying the global animal Brucella.

Description

technical field [0001] The invention relates to a Brucella abortus vaccine strain S19 marker recombinant bacterium and application thereof. Background technique [0002] Brucellosis is a zoonotic infectious disease, second only to foot-and-mouth disease among large animal infectious diseases, and has important political and economic influences. The epidemic situation in countries around the world is very serious. For a long time, the global strategy for the prevention and control of brucellosis has been mainly quarantine-culling (in developed countries) or immunization (in developing countries). The former uses quarantine and culling of sick cattle, sheep, pigs and other animals as a measure, which costs a lot of money , Difficult to operate; the latter can prevent the spread of the disease in the animal population through immunization and auxiliary culling measures, but it is difficult to distinguish the immune animals from the clinically diseased animals, which makes the d...

AI Technical Summary

Problems solved by technology

For a long time, the global strategy for the prevention and control of brucellosis has been mainly quarantine-culling (in developed countries) or immunization (in developing countries). The former uses quarantine and culling of sick cattle, sheep, pigs and other animals as a measure, which costs a lot of money , Difficult to operate; the latter can prevent the spread of the disease in the animal population through immunization and auxiliary culling measures, but it is difficult to distinguish the immune animals from the clinically diseased animals, which makes the diseased animals exist in the natural population for a long time, posing a serious threat Human and fauna health, hindering eradication and decontamination of animal brucellosis

[0003] According to the current international and domestic use, the rough vaccine strain RB51 and the vaccine strain S19 are both attenuated live vaccines, but S19 is highly virulent, and it is easy to cause abortion when inoculated into female animals. Serological methods cannot be used to distinguish infection from wild strains; The virulence of RB51 is relatively weak. Although serological differential diagnosis can be made, the immune efficacy of RB51 is controversial and has not been used in my country.

Images